AU2019304014B2 - A xinafoate salt of a jak inhibiting compound - Google Patents
A xinafoate salt of a jak inhibiting compound Download PDFInfo
- Publication number
- AU2019304014B2 AU2019304014B2 AU2019304014A AU2019304014A AU2019304014B2 AU 2019304014 B2 AU2019304014 B2 AU 2019304014B2 AU 2019304014 A AU2019304014 A AU 2019304014A AU 2019304014 A AU2019304014 A AU 2019304014A AU 2019304014 B2 AU2019304014 B2 AU 2019304014B2
- Authority
- AU
- Australia
- Prior art keywords
- fluoro
- formula
- xinafoate salt
- methylpiperazin
- mediated diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699955P | 2018-07-18 | 2018-07-18 | |
| US62/699,955 | 2018-07-18 | ||
| US201962866013P | 2019-06-25 | 2019-06-25 | |
| US62/866,013 | 2019-06-25 | ||
| PCT/EP2019/069252 WO2020016302A1 (en) | 2018-07-18 | 2019-07-17 | A xinafoate salt of a jak inhibiting compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019304014A1 AU2019304014A1 (en) | 2021-03-04 |
| AU2019304014B2 true AU2019304014B2 (en) | 2022-08-18 |
Family
ID=67396927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019304014A Active AU2019304014B2 (en) | 2018-07-18 | 2019-07-17 | A xinafoate salt of a jak inhibiting compound |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11149029B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3823964A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7422732B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102849420B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN112424187B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019304014B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021000467A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3105585A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL280025B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA53162A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021000611A (cg-RX-API-DMAC7.html) |
| MY (1) | MY209356A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202100240RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020016302A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
| WO2026132265A1 (en) | 2024-12-19 | 2026-06-25 | Astrazeneca Ab | Dry powder inhaler |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018134213A1 (en) * | 2017-01-17 | 2018-07-26 | Astrazeneca Ab | Jak1 selective inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2452965T3 (es) * | 2007-09-05 | 2014-04-03 | Rigel Pharmaceuticals, Inc. | Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina |
| RU2013114352A (ru) * | 2010-09-15 | 2014-10-20 | Ф. Хоффманн-Ля Рош Аг | Азабензотиазолы, композиции и способы применения |
| DK3063143T3 (en) * | 2013-11-01 | 2018-08-20 | Novartis Ag | Amino heteroaryl benzamides as kinase inhibitors |
| PL3189045T3 (pl) * | 2014-08-11 | 2022-04-04 | Sun Pharmaceutical Industries Limited | Nowe sole nilotynibu i jego polimorfy |
| KR102774784B1 (ko) * | 2015-09-25 | 2025-02-27 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak를 억제하기 위한 화합물 및 방법 |
| CN106831538B (zh) * | 2017-01-22 | 2019-06-25 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
-
2019
- 2019-07-17 US US16/513,781 patent/US11149029B2/en active Active
- 2019-07-17 EP EP19742558.0A patent/EP3823964A1/en active Pending
- 2019-07-17 CA CA3105585A patent/CA3105585A1/en active Pending
- 2019-07-17 AU AU2019304014A patent/AU2019304014B2/en active Active
- 2019-07-17 KR KR1020217001860A patent/KR102849420B1/ko active Active
- 2019-07-17 JP JP2021502626A patent/JP7422732B2/ja active Active
- 2019-07-17 CN CN201980047093.4A patent/CN112424187B/zh active Active
- 2019-07-17 BR BR112021000467-0A patent/BR112021000467A2/pt unknown
- 2019-07-17 WO PCT/EP2019/069252 patent/WO2020016302A1/en not_active Ceased
- 2019-07-17 MA MA053162A patent/MA53162A/fr unknown
- 2019-07-17 IL IL280025A patent/IL280025B2/en unknown
- 2019-07-17 MY MYPI2021000231A patent/MY209356A/en unknown
- 2019-07-17 SG SG11202100240RA patent/SG11202100240RA/en unknown
- 2019-07-17 CN CN202410624343.9A patent/CN118580223A/zh active Pending
- 2019-07-17 MX MX2021000611A patent/MX2021000611A/es unknown
-
2023
- 2023-10-02 JP JP2023171327A patent/JP7644190B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018134213A1 (en) * | 2017-01-17 | 2018-07-26 | Astrazeneca Ab | Jak1 selective inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| IL280025A (en) | 2021-03-01 |
| WO2020016302A1 (en) | 2020-01-23 |
| JP2024001109A (ja) | 2024-01-09 |
| KR20210033474A (ko) | 2021-03-26 |
| IL280025B1 (en) | 2024-10-01 |
| AU2019304014A1 (en) | 2021-03-04 |
| EP3823964A1 (en) | 2021-05-26 |
| JP7422732B2 (ja) | 2024-01-26 |
| JP2021530526A (ja) | 2021-11-11 |
| CA3105585A1 (en) | 2020-01-23 |
| CN112424187B (zh) | 2024-06-21 |
| CN112424187A (zh) | 2021-02-26 |
| MA53162A (fr) | 2021-05-26 |
| CN118580223A (zh) | 2024-09-03 |
| JP7644190B2 (ja) | 2025-03-11 |
| MX2021000611A (es) | 2021-04-13 |
| US11149029B2 (en) | 2021-10-19 |
| WO2020016302A8 (en) | 2020-11-12 |
| US20200062737A1 (en) | 2020-02-27 |
| KR102849420B1 (ko) | 2025-08-25 |
| MY209356A (en) | 2025-07-03 |
| BR112021000467A2 (pt) | 2021-04-06 |
| SG11202100240RA (en) | 2021-02-25 |
| IL280025B2 (en) | 2025-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7644190B2 (ja) | Jak阻害化合物のキシナホ酸塩 | |
| TWI549953B (zh) | 7-環戊基-2-(5-哌-1-基-吡啶-2-基胺基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲醯胺之鹽類及其製備方法 | |
| CN111875585B (zh) | 一类激酶抑制剂 | |
| JP7797486B2 (ja) | 新規なrho関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体 | |
| CA3034010A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| JP2020504747A (ja) | ベンズイミダゾール誘導体、調製方法およびそれらの使用 | |
| WO2009062059A2 (en) | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors | |
| TW201738232A (zh) | 吲唑之合成 | |
| TWI851336B (zh) | 腺苷受體拮抗劑化合物 | |
| TW202112768A (zh) | 二取代吡唑化合物 | |
| AU2021332886A1 (en) | Salt of rho-associated protein kinase inhibitor, solid form of the salt, preparation method for same, and uses thereof | |
| EP4393917A1 (en) | Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof | |
| EP3426640A1 (en) | Prmt5 inhibitors | |
| WO2018170199A1 (en) | Forms and compositions of a mk2 inhibitor | |
| CN113302196A (zh) | Egfr抑制剂及其组合物和应用 | |
| CN113372351A (zh) | 一类jak激酶抑制剂及其制备和应用 | |
| US20250059199A1 (en) | Solid forms of a tyk2 inhibitor, method of preparation, and use thereof | |
| CN121605107A (zh) | 2-[(3r)-2-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4[4-(氧杂环丁烷-3-基)哌嗪-1-基]-戊-2-烯腈及其溶剂化物形式的制备方法 | |
| JP2022528437A (ja) | ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途 | |
| EA044028B1 (ru) | Ксинафоатная соль соединения, ингибирующего jak | |
| CN103339124A (zh) | 二(芳氨基)芳基化合物的制备方法及其合成中间体 | |
| CN121449616A (zh) | 靶向降解细胞周期依赖性激酶的化合物及其制备方法、药物组合物和用途 | |
| WO2025003769A2 (zh) | 芳杂环并吡咯烷酮类衍生物及其用途 | |
| HK1185617A (en) | Succinate salt of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| HK1185617B (en) | Succinate salt of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |